P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR, GB2064, IN MYELOFIBROSIS

por Harrison, C., Mascarenhas, J., Rampal, R., Cilloni, D., Lindmark, B., Singh, B., Jacoby, B., Verstovsek, S.
Publicado 2022

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE...

por Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J.-J., Vannucchi, A., Verstovsek, S., Colak, G., Dey, D., Harrison, C.
Publicado 2022

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A P...

por Yacoub, A., Borate, U., Rampal, R., Ali, H., Wang, E., Gerds, A., Hobbs, G., Kremyanskaya, M., Winton, E., O’Connell, C., Goel, S., Oh, S., Schiller, G., Assad, A., Erickson-Viitanen, S., Zhou, F., Daver, N.
Publicado 2022

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

por Padron, E, Garcia-Manero, G, Patnaik, M M, Itzykson, R, Lasho, T, Nazha, A, Rampal, R K, Sanchez, M E, Jabbour, E, Al Ali, N H, Thompson, Z, Colla, S, Fenaux, P, Kantarjian, H M, Killick, S, Sekeres, M A, List, A F, Onida, F, Komrokji, R S, Tefferi, A, Solary, E
Publicado 2015

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL...

por Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.-J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al-Ali, H. K., Buxhofer-Ausch, V., Alvarez-Larrán, A., Akhani, S., Muñoz-Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.
Publicado 2022

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

por Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC, Hoffman, R
Publicado 2019